At Nimbus, we design breakthrough medicines. Utilizing our powerful structure-based drug discovery engine, we create potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. With a decade-plus track record of success, we’ve built a world-class team in both computationally driven drug discovery and early clinical development while continuing to move the needle for patients. 

Pfizer Venture Investments

RA Capital Management

Lightstone Ventures

SR One

SV Health Investors

Gates Frontier fund

Google Ventures

Atlas Venture

Bain Capital Life Sciences

BVF Partners

Lilly Ventures

Schrödinger

Bill Gates

Access Biotechnology

Biotechnology Value Fund

Surveyor Capital

Commodore Capital

Logos Capital

Nimbus Therapeutics

We were inspired by the energy in the room at the Life Science Cares Boston IMPACT breakfast this week! Proud to be a part of a community focused on giving back to our city in ways that can make a meaningful difference.

This week #Nimbi had the opportunity to join CEO Jeb Keiper and Katharine Knobil, M.D., the newest member of our Board of Directors, in a fireside chat. Kate shared many valuable insights from more than two decades of experience leading research and development at both small biotech and large pharma companies. It was a wonderful introduction, and we can’t wait to see what we will accomplish together!

Today Luke Timmerman joined #Nimbi for a special "Lunch & Learn" session. 

Most know Luke as a distinguished journalist who has been covering the #biotech sector since 2001. He is also a seasoned explorer who has led multiple expeditions around the globe, raising over $9M for causes ranging from poverty to cancer research. Our Chief Business Officer, Abbas Kazimi, joined Luke on Mount Kilimanjaro this year. And Chief Executive Officer Jeb Keiper hiked the Presidential Traverse with Luke in 2021. 

Luke shared what motivates him to be a catalyst for social impact and how he hopes to inspire others to do the same. 

You can listen to Luke’s conversation with Jeb on “The Long Run” podcast via Timmerman Report here: https://lnkd.in/ekuwTazR

We were thrilled to welcome a panel of powerhouse women in the life sciences yesterday for an inspiring conversation that was the highlight of our month-long celebration of #InternationalWomensDay. 
  
Our esteemed panelists — Rosana Kapeller, Sarah A. Solomon, Anne McGeorge and Helen Ho — shared their journeys to where they are today, the obstacles that they've navigated in their careers, and the lessons that they hope will empower the next wave of women leaders in biotech.  
   
 #WomensHistoryMonth #womenshistory #womeninscience 

Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.

Incyte

Jazz Pharmaceuticals is a global biopharmaceutical company that focuses on improving patients' lives by identifying, developing, and commercializing meaningful products that address unmet medical needs.

Jazz Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer.

Syndax

Immunocore is a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet medical needs.

Immunocore

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on RAS and mTOR signaling.

Revolution Medicines

BioNTech is a pioneering biotechnology company that develops and commercializes immunotherapies for cancer and other serious diseases.

BioNTech

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics that aim to improve outcomes for patients with rare diseases.

Mereo

Codiak Biosciences is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.

Codiak Biosciences

Aligos Therapeutics is a biotechnology company focused on developing targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses.

Aligos Therapeutics

Biopharma Informatic is a company that provides informatics solutions and services to the biopharmaceutical industry.

Biopharma Informatic

Crozet BioPharma is a biopharmaceutical company focused on developing innovative therapies for various diseases, including cancer and rare genetic disorders.

Crozet BioPharma

Galecto Inc is a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.

Galecto Inc

Morphic Holding Inc is a biotechnology company that focuses on the discovery and development of oral small-molecule integrin therapeutics.

Morphic Holding Inc

Vedanta Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases based on its microbiome-derived bacterial consortia platform.

Vedanta Biosciences Inc

Carmot Therapeutics Inc is a biotechnology company that focuses on the discovery and development of small-molecule drugs for various therapeutic areas.

Carmot Therapeutics Inc

DICE is a biotechnology company focused on developing novel therapies for immune-mediated diseases and cancer.

DICE

Artax Biopharma is a biotechnology company that specializes in the development of targeted therapies for autoimmune and inflammatory diseases.

Artax Biopharma

Landos Biopharma is a clinical-stage biotechnology company focused on the discovery and development of oral therapeutics for autoimmune diseases.

Landos Biopharma

Anagenex is a biotechnology company that focuses on small molecule drug discovery and development for various therapeutic areas.

Anagenex

NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on developing transformative therapeutics for liver and metabolic diseases, retinal diseases, and cancer.

NGM Biopharmaceuticals

CymaBay Therapeutics is a biopharmaceutical company focused on developing therapies for liver and other chronic diseases.

CymaBay Therapeutics

Nimbus Therapeutics is a biotechnology company that designs and develops small molecule therapeutics using cutting-edge tools and technologies to solve complex drug discovery challenges.

Director, Biochemistry

Director, Biochemistry & Biophysics

Associate Director, Biochemistry & Biophysics

Associate Director, Head of High Throughput Mechanistic Biology

Senior Scientist, Lead Discovery

Scientist, Biochemistry and Molecular Pharmacology

Research Fellow

Analytical Chemist

Director, Biochemistry at Nimbus Therapeutics

Aravind Basavapathruni

Executive Director

Leon Collis

Senior Director, Research Technology & Cybersecurity

Director of Informatics & Information Technology

Director of DevOps & Information Technology

Senior Director, Information Technology

Senior Director, Information Technology, DevOps & Security Officer

Director of Information Technology, DevOps & Security Officer

IT Leader – Life Sciences | Cloud Computing, DevOps, Informatics, AWS Certified Solutions Architect, AWS Certified Cloud Practitioner

James Carter

Senior Director, Contracts

Director, Contracts

Associate Director, Contracts

Manager, Proposals & Contracts

Senior Proposal Writer

Proposal & Contract Manager

Proposal & Contract Developer

Senior Administrative Assistant

Amdministrative Assistant

Receptionist

Senior Director, Contracts @ Nimbus Therapeutics | Contract Management

Jeanne Martell

Associate Director, Financial Planning & Analysis

Sr. Manager, Financial Planning & Analysis

Manager, Financial Planning & Analysis

Staff Writer

Financial Analyst

Inventory Manager / Accountant

Intern

Associate Director, Financial Planning & Analysis at Nimbus Therapeutics

Joseph Cartolano

Associate Director, Corporate Development & Strategy

Associate Director, Corporate Strategy

Senior Manager, Corporate Strategy

Senior Consultant

Consultant

Analyst

Associate, Global Business Franchise, Neurology & Immunology

Associate, Global Medical Affairs, Oncology

Corporate Development & Strategy at Nimbus Therapeutics

Leah Strickling

Chief People Officer

Vice President, Human Resources

Senior Director, Talent Acquisition and Talent Management

Senior Director, Human Resources

Director, HR Client Services

Chief People Officer at Nimbus Therapeutics

Erin Cowhig

Executive Director, Head of Biometrics

Senior Director, Biometrics

Director Biostatistics

Associate Director Biostatistics

Senior Manager Biostatistics

Manager Biostatistics

Research Associate

Intern Biostatistician

Executive Director, Biometrics at Nimbus Therapeutics

Xinyan Zhang

Executive Director Clinical Development-Oncology

Executive Director-Clinical Development

Clinical Research Director- Multiple Myeloma

Medical Director

Hematologist-Oncologist

Researcher

Frank Basile

Chief Medical Officer

Board Member

Senior Vice President, Head of Multiple Sclerosis and Immunology Development Unit

Vice President, Head of MS and Immunology Development Unit

Vice President MS RU

Clinical Research Director

Medical Director International Development

Int. Medical Affairs Director

Research Associate (permanent position)

Rheumatology fellow

Post-doctoral Fellow in Bone Biology

CMO, Nimbus Therapeutics

Nathalie Franchimont

Executive Director, Head of Information Systems

Director Research Informatics

Sr Mgr Information Systems

Associate Director

Informatics and Engineering Project Manager

Senior Investigator

Executive Director, Head of Information Systems at Nimbus Therapeutics

Rebecca Carazza

Member of the Board

Chief Financial Officer

Chief Business Officer

VP, Business Development, GSK Oncology

Head, Acquisitions and Divestitures

Director, WW Business Development

Engagement Manager

Business Development Manager

Pharmacy Pharmacoeconomic Analyst

Business Analyst

Engineering Consultant

Scientist I, Pharmaceutical Sciences

Chief Executive Officer at Nimbus Therapeutics

Jeb Keiper

Director, HR Business Partner (Discovery and Development)

Associate Director, Recruitment and Talent

Senior Manager, Recruitment and Talent

Associate Director of Talent

Executive Talent Partner

Strategy and Planning

MBA Candidate

Team Lead, Financial Services, New York Office and Research Associate, Financial Services

news impact assignment basic	general	May 6, 2024 7:48 AM	d0f49cf4
public peers	general	May 6, 2024 7:48 AM	1ce24371
news daily refresh	general	Jul 25, 2024 12:00 PM	875fc746
news processing daily refresh	general	May 21, 2024 2:51 AM	d3cdb5ce
news impact assignment daily	general
news processing basic	general	May 6, 2024 7:48 AM	be9a8fa1
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	c2ab5e21
crunchbase profile	general
li profile	general	May 6, 2024 7:48 AM	01a4cd1a
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 6, 2024 7:48 AM	167bab5d
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:NIMBUSTX

Nimbus Therapeutics